Gainers & Losers Of Feb.27: LJPC, NVAX, KTOV, CYCC, ARGS...

La Jolla Pharmaceutical Co.'S phase III trial of LJPC-501 in patients with catecholamine resistant hypotension has met the primary endpoint.

from RTT - Biotech http://ift.tt/2mEOOIS
via IFTTT